Merck & Co., Inc. filings document the regulatory record of a New Jersey pharmaceutical issuer with common stock and multiple debt securities registered on the New York Stock Exchange. The company's disclosures cover operating and financial results, clinical and regulatory matters, material agreements, governance matters and capital-structure changes.
Merck's SEC record includes Form 8-K material-event reports, definitive proxy materials and debt-financing disclosures. Recent filings describe underwritten public offerings of notes, registered securities, shareholder voting matters, board and executive-governance information, and other events tied to the company's pharmaceutical, vaccine and animal health businesses.
Merck & Co., Inc. proposes a multi‑series debt offering of unsecured senior notes, including a floating‑rate series tied to Compounded SOFR and several fixed‑rate series, to be issued in minimum denominations of $2,000. Net proceeds are intended to repay borrowings under a 364‑Day Delayed Draw Term Loan Credit Agreement entered to finance the acquisition of Terns Pharmaceuticals, Inc., which closed on May 5, 2026. The prospectus supplement discloses the Terns acquisition consideration of $53.00 per share for an approximate equity value of $6.7 billion, and states the notes will rank equally with other unsecured senior indebtedness and be structurally subordinated to subsidiaries’ liabilities.
Merck & Co., Inc. filed a Form 13F institutional holdings report signed May 13, 2026. The filing lists 14 reported holdings with a Form 13F information table value total of $349,437,632. The report names one other included manager, Merck Sharp & Dohme LLC.
Merck & Co., Inc. executive Zachary Jennifer, EVP and General Counsel, reported new equity compensation awards. She received stock options for 35,312 shares of common stock at an exercise price of $113.15 per share, vesting in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029, and expiring on 5/4/2036. She was also granted 12,064 restricted stock units, each representing a contingent right to one share of common stock, vesting and distributing in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029. Following these awards, she directly holds 70,897.254 shares of Merck common stock.
Merck & Co., Inc. executive vice president and Chief Information & Digital Officer David Michael Williams reported new equity awards. He received stock options on 13,582 shares of common stock at an exercise price of $113.15 per share and 4,640 restricted stock units, both vesting in three equal installments from 2027 to 2029. Following these awards, his directly held common stock position is reported as 31,716.037 shares.
Merck & Co., Inc. EVP & CFO Caroline Litchfield reported new equity awards in the form of stock options and restricted stock units. She now directly holds 92,300.657 shares of Merck common stock.
She received stock options for 46,566 shares at an exercise price of $113.15 per share, vesting in three equal installments on May 5, 2027, 2028, and 2029, and expiring on May 4, 2036. She also received 15,908 restricted stock units, each representing a right to one Merck share, vesting and settling in shares in three equal installments on May 5, 2027, 2028, and 2029.
Merck & Co., Inc. Executive VP & President, MRL, Dean Y. Li reported new equity awards. The filing shows a grant of 58,207 stock options with a $113.15 exercise price and a separate grant of 19,885 restricted stock units, each tied to one share of Merck common stock.
The options vest and become exercisable in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029, and expire on 5/4/2036. The restricted stock units vest and are delivered as shares on the same three annual dates. Following these transactions, Li directly holds 94,431.0500 shares of Merck common stock.
Merck & Co., Inc. executive Betty D. Larson, EVP and Chief HR Officer, reported equity awards and updated her holdings. She now directly holds 13,774 shares of Merck common stock.
On 5/5/2026, she received a grant of 23,283 stock options with an exercise price of $113.15 per share, expiring on 5/4/2036. These options vest in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029.
She was also granted 7,954 restricted stock units, each representing one share of common stock. These RSUs vest and are distributed in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029.
Merck & Co., Inc. executive Richard R. DeLuca, EVP & President of Merck Animal Health, reported compensation-related equity grants rather than open-market trades. He received 34,924 stock options with an exercise price of $113.15 per share, which vest in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029, and expire on 5/4/2036.
DeLuca also received 11,931 restricted stock units, each representing one share of Merck common stock, vesting and settling in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029. Following these grants, he holds 161,537.0700 common shares directly and 1,320.9907 shares indirectly through a 401(k) plan.
Merck & Co., Inc. Chairman, CEO & President Robert M. Davis reported new equity awards and updated his shareholdings. He now holds 450,350.757 shares of common stock directly. On May 5, 2026, he was granted 139,697 stock options with an exercise price of $113.15 per share, vesting in three equal installments on May 5, 2027, 2028 and 2029. He also received 47,724 restricted stock units, each representing a right to one Merck common share, vesting and settling in three equal installments on May 5, 2027, 2028 and 2029.
Merck & Co., Inc. reported that EVP, Specialty, Pharma, & ID Brian Foard received new equity awards. On May 5, 2026, he was granted a stock option covering 31,044 shares of common stock with an exercise price of $113.15 per share, vesting in three equal annual installments on May 5 of 2027, 2028, and 2029.
He was also granted restricted stock units for 35,351 shares and an additional 10,605 shares. Each restricted stock unit represents a contingent right to receive one share of Merck common stock and vests, with shares distributed, in three equal installments on May 5, 2027, May 5, 2028, and May 5, 2029. These are compensation grants, not open-market purchases or sales.